ClinicalTrials.gg
Not yet recruitingNCT07249476ENKLA-MUpdated Nov 19, 2026

Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia

An observational study in Leukaemia (Acute Myeloid), Leukaemia (Acute Lymphoblastic) and Myelodysplastic Syndrome, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Nantes University Hospital · Observational

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital — 4 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid, Acute · Nantes University Hospital.

Started
2026
the only one that year
Observational
3 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital, this one is the only one that started in 2026, is one of 3 observational ones, and was the 13th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Leukemia, Myeloid, Acute by Nantes University Hospital, or all of them as a file.
02

Study summary

The aim of the ENKLA-M study is to collect samples from patients with acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and myelodysplastic syndrome (MDS) to study the evolution of blast phenotype (NK receptor ligands and adhesion molecules) and the biology of patients' NK cells). To do this, blood and bone marrow samples will be collected from patients at diagnosis in order to characterize: (I) the phenotype of ALL and AML blasts with respect to NK receptor ligands and adhesion molecules; (II) the phenotypic profile of NK cells, (III) to further characterize the NK cell repertoire dynamics over time (day 30, day 60, day 90, 6 months, and 1 year), focusing on NK cell populations identified in healthy individuals as particularly effective against leukemia, by defining their phenotypic and transcriptomic profiles; and (IV) the impact of azacitidine (AZA) and donor lymphocyte infusions (DLI) on the biology of NK cells in transplanted patients. Clinical data and KIR/HLA genetic profiles will be used to analyze all NK phenotypic and functional data, with the aim of better defining: (i) the key molecular interactions between NK cells and leukemic cells; (ii) markers of NK cell anti-leukemic efficacy during hematopoietic reconstitution; and (iii) whether AZA/DLI treatment enhances the functional potential of NK cells via KIR-HLA interaction, thereby improving their effectiveness against residual disease.

03

Conditions studied

  • Leukaemia (Acute Myeloid)
  • Leukaemia (Acute Lymphoblastic)
  • Myelodysplastic Syndrome

Keywords

  • VIDAZA
  • CSH graft
  • haematopoietic stem cell
  • natural killer cells
  • NK Cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of patients with AML, ALL or MDS treated in the haematology department of Nantes University Hospital.

The number of transplants performed for these conditions in the department suggests that 55 patients could be recruited at diagnosis (30 LAM patients, 10 LAL patients and 15 SMD patients).

Among the LAM and SMD patients (n=45), we will identify 40 patients for post-transplant studies:

>20 LAM/SMD patients receiving a matched transplant:

  • 10 patients receiving AZA/Donor Lymphocyte Injection for relapse prevention.
  • 10 patients not receiving AZA/Donor Lymphocyte Injection (control group). >20 LAM/SMD patients receiving a haploidentical transplant:
  • 10 patients receiving AZA/Donor Lymphocyte Injection for relapse prevention.
  • 10 patients not receiving AZA/Donor Lymphocyte Injection (control group).

Eligibility criteria

INCLUSION CRITERIA

  • Adult patients diagnosed with acute myeloid leukaemia (LAM), acute lymphoblastic leukaemia (LAL) or myelodysplastic syndrome (SMD).
  • Adult patients receiving a HSC transplant.
  • Adult patients receiving or not AZA treatment after transplantation.
  • Patients who have signed a consent form.
  • Patients affiliated with a social security system. EXCLUSION CRITERIA
  • Minors,
  • Pregnant and/or breastfeeding women
  • Adult patients under guardianship,
  • Protected persons.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • AZA/DLI Group

    \> 20 Acute myeloid leukaemia/myelodysplastic syndrome patients receiving a matched transplant: 10 patients receiving AZA/DLI for relapse prevention. 10 patients not receiving AZA/DLI (control group). This group is monitored at diagnosis and for 12 months after transplantation.

    Other: Bone marrow sampling (during routine care) · Other: Blood samples (during routine care)

  • Group without AZA/DLI

    \> 20 Acute myeloid leukaemia/myelodysplastic syndrome patients receiving a haploidentical transplant: 10 patients receiving AZA/DLI for relapse prevention. 10 patients not receiving AZA/DLI (control group). This group is monitored at diagnosis and for 12 months after transplantation.

    Other: Bone marrow sampling (during routine care) · Other: Blood samples (during routine care)

  • LAL (Acute lymphoblastic leukaemia)

    10 Patients with a (Acute lymphoblastic leukaemia). This group is monitored at diagnosis only.

    Other: Bone marrow sampling (during routine care) · Other: Blood samples (during routine care)

Interventions

  • OtherBone marrow sampling (during routine care)

    Bone marrow sample (1 ml)

  • OtherBlood samples (during routine care)

    3 tubes of 10 ml per visit

06

What researchers measure

Primary outcomes

  1. Define the KIR and HLA genetic markers associated with an anti-leukaemic response mediated by NK cells at different stages in the progression of Acute lymphocytic leukaemia or a myalodysplasia syndrome.

    Time frame: 12 months

Secondary outcomes

  1. Assess the functional potential of different NK cell populations at diagnosis of acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndrome (at each possible relapse of the patient).

    Time frame: 12 months

  2. Assess NK cell reconstitution during transplant of hematopoietic stem cells.

    Time frame: 12 months

  3. Assess the impact of the hypomethylating agent AZA used to prevent relapse after allogeneic transplantation for acute myeloid leukaemia or myelodysplastic syndrome on NK cells.

    Time frame: 12 months

  4. Assess the impact of Donor Lymphocyte Injection used in the prevention of post-allogeneic transplant relapse on NK cells.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 36 months is below that.

Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jun 2026 → Dec 2026, primary completion Jun 2029 → Dec 2029 and completion Jun 2030 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartEst.
Dec 1, 2026was Jun 2026
Primary completionEst.
Dec 1, 2029was Jun 2029
CompletionEst.
Dec 1, 2030was Jun 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Dec 1, 2026
Nov 19, 2026
Primary completion
Jun 1, 2029→Dec 1, 2029
Nov 19, 2026
Study completion
Jun 1, 2030→Dec 1, 2030
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Jun 1, 2026→Dec 1, 2026
    Primary completion Jun 1, 2029→Dec 1, 2029
    Study completion Jun 1, 2030→Dec 1, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07249476
Collaborators
EFS CPDL: French Blood Establishment Centre-Pays de la Loire
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Sponsor department
Contact
bp-prom-regl@chu-nantes.fr
+33253482835
Patrice CHEVALLIER
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion